FrancophonIA/ELRC3.0 huggingface dataset:
English: In a Phase 3 placebo-controlled study in patients with PAH, mean absolute changes in haemoglobin at regular visits compared to baseline ranged from −0.34 to −0.02 g/dL in the selexipag group compared to −0.05 to 0.25 g/dL in the placebo group.
Croatian: U placebom kontroliranom ispitivanju faze 3 u bolesnika s PAH-om srednje vrijednosti apsolutnih promjena hemoglobina pri redovnim posjetima u usporedbi s početnim vrijednostima bile su u rasponu od −0,34 do −0,02 g/dl u skupini koja je primala seleksipag, u usporedbi s −0,05 do 0,25 g/dl u skupini koja je primala placebo.
English: Tortuosity of retinal arterioles was noted after 2 years of treatment only in rats.
Croatian: Nakon 2 godine liječenja samo su u štakora zabilježeni tortuoziteti arteriola mrežnice.
English: Uptravi should not be used during breast-feeding.
Croatian: Uptravi se ne bi trebao primjenjivati tijekom dojenja.
English: Uptravi is a medicine that contains the active substance selexipag.
Croatian: Uptravi je lijek koji sadrži djelatnu tvar seleksipag.
English: The diagram below shows the number of tablets to take every morning and every evening for the first 4 steps.
Croatian: Shema ispod prikazuje broj tableta koji trebate uzeti svakog jutra i svake večeri tijekom prva 4 koraka.
English: Intra-subject variability in exposure was 24% and 19% for selexipag and the active metabolite, respectively.
Croatian: Varijabilnost izloženosti u pojedinog bolesnika bila je 24% za seleksipag i 19% za aktivni metabolit.
English: Mild, transient nausea was the only reported consequence.
Croatian: Jedina zabilježena posljedica bila je blaga prolazna mučnina.
English: Please read the accompanying patient information leaflet before starting treatment.
Croatian: Molimo Vas da prije početka liječenja pročitate priloženu uputu o lijeku.
English: Nasal congestion
Croatian: nazalna kongestija
English: Your doctor may decide to restart your treatment on a lower dose, gradually increasing to your previous maintenance dose.
Croatian: Vaš liječnik može odlučiti da ponovno počnete liječenje s nižom dozom i postupno ju povećavate do svoje prethodne doze održavanja.
English: Animal studies indicated an increased risk of intussusception, but the clinical relevance of these findings is unknown (see section 5.3).
Croatian: Ispitivanja na životinjama pokazala su povećan rizik od intususcepcije, ali klinički značaj ovih nalaza nije poznat
English: In a fertility study performed in rats, a prolongation of oestrus cycles resulting in increases in days until copulation was observed at exposures 173-fold above therapeutic exposures (based on total exposures), the no-observed-effect level being 30-fold above therapeutic exposures.
Croatian: U ispitivanjima plodnosti provedenima na štakorima, uočeno je produljenje estrusnih ciklusa s posljedicom porasta broja dana do kopulacije pri izloženostima 173 puta većim od izloženosti pri liječenju (temeljeno na ukupnim izloženostima), s razinom bez zapažene štetne posljedice pri 30 puta većoj izloženosti od izloženosti pri liječenju.
English: The recommended starting dose is 200 micrograms given twice daily, approximately 12 hours apart.
Croatian: Preporučena početna doza je 200 mikrograma uzeto dva puta dnevno, u razmaku od približno 12 sati.
English: In patients with severe renal impairment (eGFR < 30 mL/min/1.73 m2), caution should be exercised during dose titration.
Croatian: U bolesnika s teškim oštećenjem funkcije bubrega (eGFR < 30 ml/min/1,73 m2), titraciju treba provoditi uz oprez.
English: The patient titration guide along with the Patient Information Leaflet should be given to the patient after the demonstration.
Croatian: Vodič za titraciju doze za bolesnika zajedno s uputom o lijeku treba dati bolesniku nakon razgovora.
English: A delay in the closure of the femoral and/or tibial epiphyseal growth plate was observed in juvenile dogs.
Croatian: U mladih pasa uočena je odgoda zatvaranja epifiznih ploča rasta femura i/ili tibije.
English: Subjects with severe hepatic impairment (Child-Pugh class C) showed similar predicted exposure at steady state as subjects with moderate hepatic impairment during a once-daily regimen.
Croatian: Ispitanici s teškim oštećenjem funkcije jetre (Child-Pugh stadij C) pokazali su sličnu predviđenu izloženost u stanju dinamičke ravnoteže kao ispitanici s umjerenim oštećenjem jetrene funkcije tijekom režima doziranja jednom dnevno.
English: The dose is increased in increments of 200 micrograms given twice daily, usually at weekly intervals.
Croatian: Doza se povećava u koracima povećanja od 200 mikrograma uzeto dva puta dnevno, obično u razmacima od tjedan dana.
English: For patients with moderate hepatic impairment (Child-Pugh class B), the starting dose of Uptravi should be 200 micrograms once daily, and increased at weekly intervals by increments of 200 micrograms given once daily until adverse reactions, reflecting the mode of action of selexipag, that cannot be tolerated or medically managed are experienced.
Croatian: Za bolesnike s umjerenim oštećenjem funkcije jetre (Child-Pugh stadij B) početna doza Uptravija treba biti 200 mikrograma jednom dnevno, a zatim ju treba povećavati u razmacima od tjedan dana s koracima povećanja od 200 mikrograma uzeto jednom dnevno, sve do pojave nuspojava zbog načina djelovanja seleksipaga koje se ne mogu podnositi ni zbrinuti lijekovima.
English: A no-observed-adverse-effect level was not established.
Croatian: Nije ustanovljena razina bez zapažene štetne posljedice.
English: Interruptions and discontinuations
Croatian: Prekidi i prestanak uzimanja
English: In a Phase 3 placebo-controlled study in patients with PAH, hyperthyroidism was reported for 1.6% of patients in the selexipag group, compared to no case in the placebo group (see section 4.4).
Croatian: U placebom kontroliranom ispitivanju faze 3 u bolesnika s PAH-om hipertireoza je zabilježena u 1,6% bolesnika u skupini koja je primala seleksipag dok u skupini koja je primala placebo nije zabilježen nijedan slučaj (vidjeti dio 4.4).
English: In patients in whom up-titration was limited by reasons other than adverse reactions reflecting the mode of action of Uptravi, a second attempt to continue up-titration to the highest individually tolerated dose up to a maximum dose of 1,600 micrograms twice daily may be considered.
Croatian: U bolesnika u kojih je povećanje doze ograničeno razlozima koji nisu povezani s nuspojavama zbog načina djelovanja Uptravija, može se razmotriti ponovni pokušaj povećanja doze na najveću dozu koju bolesnik može podnositi do najviše 1600 mikrograma dva puta dnevno.
English: The film-coated tablets are to be taken orally in the morning and in the evening.
Croatian: Filmom obložene tablete namijenjene su uzimanju kroz usta ujutro i navečer.
English: Approximately 1%, 46%, 53%, and 1% of patients were in WHO FC I, II, III and IV, respectively, at baseline.
Croatian: Približno je 1% bolesnika bilo s WHO FC I, 46% s WHO FC II, 53% s WHO FC III i 1% s WHO FC IV na početku ispitivanja.
English: Titration Guide
Croatian: Vodič za titraciju
English: In adult and juvenile dogs, intestine and bone / bone marrow were identified as the main target organs after treatment with selexipag.
Croatian: U odraslih i mladih pasa nakon liječenja seleksipagom ustanovljeno je da su glavni ciljni organi crijevo i kost/koštana srž.
English: Patients titrating selexipag to an individually tolerated dose (200 micrograms twice daily increments up to 800 micrograms twice daily; N = 33) achieved a statistically significant mean reduction in pulmonary vascular resistance of 30.3% (95% confidence interval [CI]: −44.7%, −12.2%; p = 0.0045) and an increase in cardiac index (mean treatment effect) of 0.48 L/min/m2 (95% CI: 0.13, 0.83) compared to placebo (N = 10).
Croatian: Bolesnici kojima se seleksipag titrirao do individualno tolerirane doze (u koracima povećanja od 200 mikrograma dva puta dnevno do 800 mikrograma dva puta dnevno; N = 33) postigli su statistički značajno smanjenje srednje vrijednosti plućnog vaskularnog otpora od 30,3% (95% interval pouzdanosti [CI]: −44,7%; −12,2%; p = 0,0045) te povećanje srčanog indeksa (srednji učinak liječenja) od 0,48 l/min/m2 (95% CI: 0,13; 0,83) u usporedbi s placebom (N = 10).
English: No adjustment to the dose regimen is needed in patients with mild or moderate renal impairment.
Croatian: Nije potrebna prilagodba režima doziranja u bolesnika s blagim ili umjerenim oštećenjem funkcije bubrega.
English: Notes:
Croatian: Bilješke:
English: Increase in heart rate
Croatian: Povećanje frekvencije srca
English: It could take several weeks to find the dose that is right for you.
Croatian: Pronalaženje prave doze za Vas može potrajati nekoliko tjedana.
English: Based on modelling and simulation data from a study in subjects with hepatic impairment, the exposure to selexipag at steady state in subjects with moderate hepatic impairment (Child-Pugh class B) after a once-daily regimen is predicted to be approximately 2-fold higher than that in healthy subjects during a twice-daily regimen.
Croatian: Temeljeno na modeliranju i simulaciji podataka iz ispitivanja u ispitanika s oštećenjem funkcije jetre, predviđa se da će izloženost seleksipagu u stanju dinamičke ravnoteže u ispitanika s umjerenim oštećenjem funkcije jetre (Child-Pugh stadij B) nakon režima doziranja jednom dnevno biti približno dvostruko veća od izloženosti u zdravih ispitanika tijekom režima doziranja dva puta dnevno.
English: Your doctor or nurse may have you resume treatment at a lower dose, gradually increasing to your previous maintenance dose.
Croatian: Vaš liječnik ili medicinska sestra može odlučiti da nastavite liječenje s nižom dozom i postupno ju povećavate do svoje prethodne doze održavanja
English: This is one 200 microgram tablet in the morning and another 200 microgram tablet in the evening.
Croatian: To je jedna tableta od 200 mikrograma ujutro i još jedna tableta od 200 mikrograma navečer.
English: Hospitalisation for PAH was observed in 86 (15.0%) patients on selexipag and 123 (21.1%) patients on placebo.
Croatian: Hospitalizacija zbog PAH-a zabilježena je u 86 (15,0%) bolesnika koji su primali seleksipag i 123 (21,1%) bolesnika koji su primali placebo.
English: For a full list of side effects see package leaflet for further information.
Croatian: Za cjeloviti popis nuspojava pogledajte uputu o lijeku za daljnje informacije.
English: The observed effect of selexipag versus placebo on the primary endpoint was consistent across individualised maintenance dose as shown by the hazard ratio for the three pre-defined categories (0.60 for 200-400 micrograms twice daily, 0.53 for 600-1,000 micrograms twice daily, and 0.64 for 1,200-1,600 micrograms twice daily), which was consistent with the overall treatment effect (0.60).
Croatian: Zapažen učinak seleksipaga na primarnu mjeru ishoda, u usporedbi s placebom, bio je dosljedno prisutan kroz sve individualizirane doze održavanja, što je pokazao omjer hazarda za tri prethodno definirane kategorije (0,60 za dozu 200-400 mikrograma dva puta dnevno, 0,53 za dozu 6001000 mikrograma dva puta dnevno te 0,64 za dozu 1200-1600 mikrograma dva puta dnevno), a što je bilo u skladu s ukupnim učinkom liječenja (0,60).
English: Exposure to the active metabolite remained almost unchanged in subjects with mild hepatic impairment and was doubled in subjects with moderate hepatic impairment.
Croatian: Izloženost aktivnom metabolitu ostala je gotovo nepromijenjena u ispitanika s blagim oštećenjem funkcije jetre, a udvostručila se u ispitanika s umjerenim oštećenjem funkcije jetre.
English: Please see section Maintenance dose below for more information.
Croatian: Za više informacija pogledajte niže naveden dio Doza održavanja.
English: Diarrhoea* Vomiting * Nausea*
Croatian: povraćanje* mučnina*
English: If you forget to take Uptravi, take a dose as soon as you remember, then continue to take your tablets at the usual times.
Croatian: Ako zaboravite uzeti Uptravi, uzmite dozu čim se sjetite, a potom nastavite uzimati svoje tablete u uobičajeno vrijeme.
English: Safety margins for potential IP receptor-related effects on reproduction were 20 for fertility and 5 and 1 (based on free exposure) for embryo-foetal development in rats and rabbits, respectively, when adapted for differences in receptor potency.
Croatian: 20 za plodnost te 5 i 1 (temeljeno na slobodnoj izloženosti) za embriofetalni razvoj u štakora odnosno kunića, nakon prilagodbe zbog razlike u potentnosti receptora.
English: Uptravi should be used with caution in this age group.
Croatian: U ovoj dobnoj skupini Uptravi treba oprezno primjenjivati.
English: The number of patients who experienced, as a first event, death due to PAH or hospitalisation for PAH up to end of treatment was 102 (17.8%) in the selexipag group and 137 (23.5%) in the placebo group.
Croatian: Broj bolesnika koji su kao prvi događaj imali smrt zbog PAH-a ili hospitalizaciju zbog PAH-a do kraja liječenja bio je 102 (17,8%) u skupini koja je primala seleksipag i 137 (23,5%) u skupini koja je primala placebo.
English: Cartons of 10 or 60 film-coated tablets, and 60 or 140 film-coated tablets (titration packs).
Croatian: Kutije s 10 ili 60 filmom obloženih tableta, i 60 ili 140 filmom obloženih tableta (pakiranja za titraciju doze).
English: No adjustment to the dose regimen is needed in patients with mild hepatic impairment (Child-Pugh class A).
Croatian: Nije potrebna prilagodba režima doziranja u bolesnika s blagim oštećenjem funkcije jetre (Child-Pugh stadij A).
English: • Cover letter to the healthcare professional;
Croatian: • Sažetak opisa svojstava lijeka za Uptravi; • Popratno pismo za zdravstvenog radnika;
English: Treatment with selexipag 200-1,600 micrograms twice daily resulted in a 40% reduction (hazard ratio [HR] 0.60; 99% CI: 0.46, 0.78; one-sided log-rank p value < 0.0001) of the occurrence of morbidity or mortality events up to 7 days after last dose compared to placebo (Figure 1).
Croatian: Liječenje seleksipagom u dozi od 200-1600 mikrograma dva puta dnevno imalo je za posljedicu 40%-tno smanjenje (omjer hazarda [HR] 0,60; 99% CI: 0,46; 0,78; jednostrana p-vrijednost dobivena log-rank testom< 0,0001) pojave događaja morbiditeta ili mortaliteta do 7 dana nakon zadnje doze u usporedbi s placebom (Slika 1).
English: The finding did not occur in mouse or rat toxicity studies.
Croatian: Nalaz se nije javio u ispitivanjima toksičnosti na miševima ili štakorima.
English: Inducers of CYP2C8
Croatian: Induktori CYP2C8
English: Given that the majority of the pharmacological effect is driven by the active metabolite, this effect is not clinically relevant.
Croatian: S obzirom da je nositelj glavnine farmakološkog djelovanja aktivni metabolit, ovaj učinak nije klinički značajan.
English: The risk of an event for this endpoint was reduced by 30% in patients receiving selexipag compared to placebo (HR 0.70, 99% CI: 0.50, 0.98; one-sided log-rank p = 0.0031).
Croatian: Rizik od pojave događaja za ovu mjeru ishoda bio je smanjen za 30% u bolesnika koji su primali seleksipag u usporedbi s placebom (HR 0,70; 99% CI: 0,50; 0,98; jednostrana p-vrijednost dobivena log-rank testom = 0,0031).
English: Do not use Uptravi after the expiry date, which is stated on the carton and on the blister after “EXP.” The expiry date refers to the last day of that month.
Croatian: Uptravi se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake "EXP".
English: The approximate rate of adverse reactions that were serious was 2.3% in the selexipag group and 0.5% in the placebo group.
Croatian: Približan udio ozbiljnih nuspojava bio je 2,3% u skupini koja je primala seleksipag te 0,5% u skupini koja je primala placebo.
English: Inhibitors of CYP2C8
Croatian: Inhibitori CYP2C8
English: Dosing frequency of Uptravi should be reduced to once daily when co-administered with moderate CYP2C8 inhibitors (e.g., clopidogrel, deferasirox, teriflunomide).
Croatian: Učestalost doziranja lijeka Uptravi treba smanjiti na jedanput dnevno kada se primjenjuje istodobno s umjerenim inhibitorima CYP2C8 (npr. klopidogrelom, deferasiroksom i teriflunomidom).
English: Uptravi has minor influence on the ability to drive and use machines.
Croatian: Uptravi malo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Concomitant administration of Uptravi with clopidogrel (loading dose of 300 mg or maintenance dose of 75 mg once a day), a moderate inhibitor of CYP2C8, had no relevant effect on the exposure to selexipag but increased the exposure to the active metabolite approximately 2.2 and 2.7-fold following loading dose and maintenance dose, respectively.
Croatian: Istodobna primjena lijeka Uptravi s klopidogrelom (udarna doza od 300 mg ili doza održavanja od 75 mg jednom dnevno), umjerenim inhibitorom CYP2C8, nije imala značajan utjecaj na izloženost seleksipagu, ali te je povećala izloženost aktivnom metabolitu oko 2,2 i 2,7 puta nakon udarne doze odnosno doze održavanja.
English: In subjects with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment, exposure to selexipag was 2- and 4-fold higher, respectively, when compared to healthy subjects.
Croatian: U ispitanika s blagim (Child-Pugh stadij A) ili umjerenim (Child-Pugh stadij B) oštećenjem funkcije jetre izloženost seleksipagu bila je 2 odnosno 4 puta veća, u usporedbi sa zdravim ispitanicima.
English: This is called titration.
Croatian: To se naziva titracija doze.
English: Adverse reactions associated with the mode of action of selexipag have been observed frequently, in particular during the phase of individualised dose titration, and are tabulated below:
Croatian: Farmakološki učinci povezani s titracijom i dozom održavanja Nuspojave povezane s načinom djelovanja seleksipaga uočene su često, posebice tijekom faze individualizirane titracije doze; navedene su u tablici ispod: Nuspojave koje nastaju zbog sličnosti s prostaciklinima
English: Your doctor may have you step up from the starting dose to higher doses of Uptravi.
Croatian: Vaš liječnik može Vam povećavati dozu Uptravija od početne doze prema većima.
English: With each step, you will add one 200 microgram tablet to your morning dose and another 200 microgram tablet to your evening dose.
Croatian: Sa svakim korakom, dodat ćete jednu tabletu od 200 mikrograma svojoj jutarnjoj dozi i još jednu tabletu od 200 mikrograma svojoj večernjoj dozi.
English: Do not stop taking Uptravi unless your doctor or nurse tells you to.
Croatian: Ako prestanete uzimati Uptravi Nemojte prekidati uzimanje Uptravija ukoliko Vam to ne kaže liječnik ili medicinska sestra.
English: 60 or 140 film-coated tablets Titration pack
Croatian: 60 ili 140 filmom obloženih tableta Pakiranje za titraciju doze
English: If you forget to take Uptravi.....................................16 If you stop taking Uptravi.........................................17 Titration diary...........................................................18
Croatian: Ako prestanete uzimati Uptravi .............................17
English: There are treatments available that can help relieve the side effects.
Croatian: Postoje dostupni lijekovi koji mogu pomoći olakšati nuspojave.
English: (a) % of patients with an event at 36 months = 100 × (1 - Kaplan-Meier estimate); hazard ratio estimated using Cox's proportional hazard model; unstratified one-sided log-rank p-value (b) % of patients with an event as part of the primary endpoint up to EOT + 7 days; hazard ratio estimated using Aalen Johansen method; 2-sided p-value using Gray's test (c) Includes ‘Need for lung transplantation or atrial septostomy' (1 patient on selexipag and 2 on placebo) (d) % of patients with an event up to EOT + 7 days or up to study closure; hazard ratio estimated using Cox's proportional hazard model; unstratified one-sided log-rank p-value
Croatian: (a) % bolesnika s događajem u 36 mjeseci = 100 × (1 - Kaplan-Meier procjena); omjer hazarda procijenjen Coxovim modelom proporcionalnog hazarda; jednostrana p-vrijednost dobivena nestratificiranim log-rank testom (b) % bolesnika s događajem kao dijelom primarne mjere ishoda do EOT + 7 dana; omjer hazarda procijenjen AalenJohansenovom metodom; dvostrana p-vrijednost dobivena Grayevim testom
English: Idiopathic or heritable PAH was the most common aetiology in the study population (58%) followed by PAH due to connective tissue disorders (29%), PAH associated with simple corrected congenital heart disease (10%), and PAH associated with other aetiologies (drugs and toxins [2%] and HIV
Croatian: U ispitivanoj populaciji etiološki je najčešći bio idiopatski ili nasljedni PAH (58%), zatim PAH zbog bolesti vezivnog tkiva (29%) PAH povezan s korigiranom jednostavnom prirođenom srčanom manom
English: Over time, your doctor or nurse may adjust your maintenance dose as needed.
Croatian: Vaš liječnik ili medicinska sestra može prilagoditi Vašu dozu održavanja prema potrebi.
English: Decreased appetite Weight decrease
Croatian: Poremećaji metabolizma i prehrane smanjen apetit smanjenje težine
English: Only two subjects with severe (Child-Pugh class C) hepatic impairment were dosed with selexipag.
Croatian: Samo su dva ispitanika s teškim (Child-Pugh stadij C) oštećenjem funkcije jetre primala seleksipag.
English: Mannitol (E421), maize starch, low substituted hydroxypropyl cellulose, hydroxypropyl cellulose, magnesium stearate.
Croatian: Manitol (E421), kukuruzni škrob, djelomično supstituirana hidroksipropilceluloza, hidroksipropilceluloza, magnezijev stearat.
English: Death due to PAH as a component of the endpoint was observed in 16 (2.8%) patients on selexipag and 14 (2.4%) on placebo.
Croatian: Smrt zbog PAH-a kao komponenta mjere ishoda zabilježena je u 16 (2,8%) bolesnika koji su primali seleksipag i 14 (2,4%) bolesnika koji su primali placebo.
English: The glucuronidation of the active metabolite is catalysed by UGT1A3 and UGT2B7.
Croatian: Glukuronidaciju aktivnog metabolita kataliziraju UGT1A3 i UGT2B7.
English: If it is within 6 hours of when you would normally take your next dose, you should skip the missed dose and continue to take your medicine at the usual time.
Croatian: Ako ima manje od 6 sati do vremena kad biste obično uzeli sljedeću dozu, trebate preskočiti zaboravljenu dozu i nastaviti uzimati svoj lijek u uobičajeno vrijeme.
English: Selexipag is rapidly absorbed and is hydrolysed by carboxylesterases to its active metabolite.
Croatian: Apsorpcija Seleksipag se brzo apsorbira i hidrolizira putem karboksilesteraza u svoj aktivni metabolit.
English: Your doctor or nurse can prescribe an equivalent single-tablet strength for your maintenance dose.
Croatian: Vaš Vam liječnik ili medicinska sestra može propisati odgovarajuću jačinu u jednoj tableti za dozu održavanja.
English: The patients will receive an identical titration guide and Patient Leaflet in their titration packs of Uptravi.
Croatian: Isti takav vodič za titraciju i uputu o lijeku bolesnici će dobiti u svom pakiranju za titraciju doze
English: If it is nearly time for your next dose (within 6 hours before you would normally take it), you should skip the missed dose and continue to take your medicine at the usual time.
Croatian: Ako je uskoro vrijeme za Vašu sljedeću dozu (manje od 6 sati do redovnog uzimanja) preskočite zaboravljenu dozu i nastavite uzimati svoj lijek u uobičajeno vrijeme.
English: Page 8
Croatian: Stranica 8
English: Patients were randomised to either placebo (N = 582) or selexipag (N = 574) twice daily.
Croatian: Bolesnici su bili randomizirani kako bi primali placebo (N = 582) ili seleksipag
English: If the therapy is not tolerated at a given dose, symptomatic treatment and/or a dose reduction to the next lower dose should be considered.
Croatian: Ako bolesnik ne podnosi terapiju u danoj dozi, treba razmotriti liječenje simptoma i/ili smanjenje doze na sljedeću nižu dozu.
English: In the presence of 600 mg rifampicin, once a day, an inducer of CYP2C8 (and UGT enzymes), the exposure to selexipag did not change, whereas exposure to the active metabolite was reduced by half.
Croatian: U prisutnosti 600 mg rifampicina, jedanput dnevno, induktora CYP2C8 (i UGT enzima), izloženost seleksipagu nije se promijenila, dok se izloženost aktivnom metabolitu smanjila za pola.